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BACKGROUND: Rhabdomyosarcomas (RMSs) are primarily paediatric sarcomas that resemble developing skeletal muscle. Our aim
was to determine the effects of microRNAs (miRNA) that have been implicated in muscle development on the clinical behaviour
of RMSs.
METHODS: Expression levels of miR-1, miR-206, miR-133a and miR-133b were quantified by RT–PCR in 163 primary paediatric RMSs,
plus control tissues, and correlated with clinico-pathological features. Correlations with parallel gene expression profiling data for
84 samples were used to identify pathways associated with miR-206. Synthetic miR-206 was transfected into RMS cell lines and
phenotypic responses assessed.
RESULTS: Muscle-specific miRNAs levels were lower in RMSs compared with skeletal muscle but generally higher than in other normal
tissues. Low miR-206 expression correlated with poor overall survival and was an independent predictor of shorter survival in
metastatic embryonal and alveolar cases without PAX3/7-FOXO1 fusion genes. Low miR-206 expression also significantly correlated
with high SIOP stage and the presence of metastases at diagnosis. High miR-206 expression strongly correlated with genes linked to
muscle differentiation and low expression was associated with genes linked to MAPkinase and NFKappaB pathway activation.
Increasing miR-206 expression in cell lines inhibited cell growth and migration and induced apoptosis that was associated with
myogenic differentiation in some, but not all, cell lines.
CONCLUSION: miR-206 contributes to the clinical behaviour of RMSs and the pleiotropic effects of miR-206 supports therapeutic
potential.
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Rhabdomyosarcoma (RMS) are a heterogenous group of sarcomas
that account for over half the cases of soft tissue sarcomas in
children (Slater and Shipley, 2007). Although the cure rate for
patients with localised disease is around 70%, the presence of
metastasis is associated with a much poorer prognosis (Breneman
et al, 2003; Oberlin et al, 2008). In addition, current treatment
modalities confer significant morbidity and less toxic treatments
are urgently needed (Stevens, 2005). Better stratification for
current protocols is also required, potentially incorporating the
molecular characteristics of RMS (Oberlin et al, 2008; Davicioni
et al, 2009). Histologically, there are two major subtypes:
embryonal (ERMS), which account for 60–70% of cases, and
alveolar (ARMS). Approximately 70% of ARMS harbour fusion
genes resulting from 50 sequences of PAX3 or PAX7 genes fusing to
30 sequences of FOXO1 (Galili et al, 1993; Shapiro et al, 1993; Davis
et al, 1994). Alveolar cases with PAX3-FOXO1 are characterised by
metastatic behaviour and a poor prognosis. No such molecular
marker is predictive of clinical behaviour in the embryonal
subtype. Although the cell of origin is currently unknown,
(Linardic et al, 2005; Mercado and Barr, 2007) the defining
characteristic of RMS is that they show myogenic features and are
composed of cells that fail to undergo terminal differentiation
(Merlino and Helman, 1999).
MicroRNAs (miRNAs) are small (20–22nt) RNA molecules that
function by negatively regulating the stability or translational
efficiency of their target mRNAs, most commonly by base-pairing
to partially complementary sequences within the 30 UTR (Kim,
2005; Esquela-Kerscher and Slack, 2006). miRNAs are involved in
diverse biological processes including apoptosis, cellular prolifera-
tion and differentiation. It is noteworthy that they have shown
oncogenic or tumour suppressor roles in different cancers types
and miRNA profiles can identify diagnostic/prognostic charac-
teristics (Calin et al, 2002; Lu et al, 2005; Roldo et al, 2006; Volinia
et al, 2006; Yanaihara et al, 2006). It is suggested that miRNAs
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Petri et al, 2009).
A role for miRNAs in the myogenic programme has been
identified. miR-1 and miR-206 are essential for the formation of
differentiated skeletal muscle cells (Sokol and Ambros, 2005; Zhao
et al, 2005; Chen et al, 2006; Kim et al, 2006; Rao et al, 2006).
Although miR-206 is almost exclusively expressed in skeletal
muscle, miR-1 is also highly expressed in heart muscle and, to a
lesser extent, in other tissues including bladder and prostate
(Baskerville and Bartel, 2005; Kim et al, 2006; Liang et al, 2007).
miR-133a and miR-133b have been associated with myoblast
proliferation (Chen et al, 2006). In addition, miR-1 and miR-206
have been shown to be expressed at a lower level in RMS compared
with normal skeletal muscle (Subramanian et al, 2008; Wang et al,
2008; Taulli et al, 2009; Yan et al, 2009). However, these studies
were performed on small populations of patient samples not
suitable to identify correlations between miRNA expression levels
and clinico-pathological features. Recently, increasing expression
of miR-1 and miR-206 in two RMS cell lines was shown to induce
myogenic differentiation and, for miR-206, inhibition of cell line
growth (Taulli et al, 2009; Yan et al, 2009). Significantly, the degree
of myogenic differentiation in RMS has been inversely related to
proliferation and migration (Lollini et al, 1991; Merlino and
Helman, 1999; Barlow et al, 2006; Davicioni et al, 2009).
We have analysed a large series of primary RMS samples for
miR-1, miR-206, miR-133a and miR-133b expression levels to
identify correlations with clinical behaviour. In view of recent
results emphasising the biological and clinical effect of fusion gene
status in RMS, including our own survival analyses (Davicioni
et al, 2006, 2009; Williamson et al, 2010), we have performed
comparisons considering either all samples or samples divided by
their fusion status (either positive or negative for PAX3/7-FOXO1).
Strong correlations were identified with miR-206 levels that
clinically stratify embryonal and alveolar fusion gene-negative
RMS. Comparison with parallel expression profiling data and
functional analyses after modulating miR-206 levels in cell lines
identified likely biological mechanisms underlying the clinical
behaviour. Furthermore, the various tumour suppressive effects of
increasing miR-206 described here and elsewhere are consistent
with therapeutic opportunities for RMS patients.
MATERIALS AND METHODS
Primary tumour samples
In total, 163 primary RMS tumours samples from resection or
biopsy material and 15 normal skeletal muscle tissues were snap
frozen and collected from different centres. Total RNA was
extracted as previously described (Williamson et al, 2005). RNA
from normal lung, colon, brain and thyroid was commercially
available (Clontech, Mountain View, CA, USA). All primary
tumours were pathologically reviewed and their fusion gene status
determined (Williamson et al, 2005). This study had ethical
approval (local research ethics committee protocol no. 1836, multi-
regional research ethics committee/98/4/023) and, wherein re-
quired, consent had been obtained. All patients were treated
similarly with multi-agent chemotherapy and surgery, with or
without radiotherapy for local control. High-dose therapy with
bone marrow or stem-cell rescue in first remission was limited to
high-risk patients. Patients were registered to, or treated accord-
ing to, the MMT 89 (Stevens, 2005), MMT 95 (Defachelles et al,
2009) and EpSSG RMS 05 protocols for localised RMS and
MMT IV 89/91 or MMT 98 (Bergeron et al, 2008; Oberlin et al,
2008) for metastatic RMS. The clinico-pathological information
and correlations with overall survival, including previously defined
parameters, (Oberlin et al, 2008) are summarised in Table 1 and
Supplementary Table 1.
Cell lines
Human cell lines derived from ERMS and ARMS were used in this
study. The sources of these, their culture conditions and DNA
fingerprint data used for identity verification are summarised in
Supplementary Table 2. A primary culture of human myoblasts
was also available.
Quantitative real-time PCR for miRNA detection
The TaqMan miRNA assay was used according to the manufac-
turer’s instructions to measure the expression of miR-1, miR-133a,
miR-133b and miR-206 using pre-developed reagents from ABI
(Applied Biosystems, Carlsbad, CA, USA) run on an ABI 7900HT
Real-Time PCR machine. U6 small nuclear RNA (RNU6B) and
small nucleolar RNA, C/D box 48 (RNU48) were used as
endogenous controls to normalise the data. Analysis was
performed by the comparative threshold cycle (Ct) method
accordingly to User Bulletin no. 2 (Applied Biosystems). Results
Table 1 Clinical-pathological data of the patients involved in this study
and their association with overall survival
Parameter
No. of
patients in
TaqMan analysis
No. of
patients in
microarray analysis
Histology
ERMS 66 (41%) 31 (37%)
ARMS 90 (55%) 53 (63%)
PAX3-FOXO1 fusion
gene-positive
45 30
PAX7-FOXO1 fusion
gene-positive
12 8
Fusion gene-negative 33 15
RMS not otherwise
specified
7 (4%) 0
Total 163 84
Gender (M/F) 91/72 47/37
Median age 5 (0–23) 5.5 (0–21)
Primary tumour location
Favourable 58 32
Unfavourable 79 50
Unknown 26 2
SIOP stage
Stage I 46 25
Stage II 44 26
Stage III 21 9
Stage IV 43 22
Unknown 9 2
Metastasis
Present at diagnosis 43 22
Absent at diagnosis 108 61
Unknown 12 1
Median survival
Median follow-up time 4.0y
a
Overall survival 9.6y
N of events (N patients) 61 (159)
Event-free survival 2.8y
N of events (N patient) 79 (159)
Abbreviations: ARMS¼alveolar RMS; ERMS¼embryonal RMS; RMS¼ rhabdo-
myosarcoma.
aOn the basis of patients with censored data.
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the two endogenous controls and all experiments were performed
in triplicate. As the distribution of miRNA expression was not
found to be normal (Shapiro–Wilk normality test), differential
expression between subgroups was performed using non-
parametric tests namely Mann–Whitney U-test and Kruskal–
Wallis rank sum test. Log-rank test and Cox’s proportional hazards
regression were used to test the correlation of categorical or
continuous parameters to overall or disease-free survival. For this
latter analysis, we considered the time to the first progression of
the disease (either as local relapse or distant metastasis). Patients
who died without going through clinical stabilisation of their
disease were censored at their death. The expression of miRNAs
showed a heavy tailed distribution (particularly the left) with only
3–4 Cts difference within samples between the 25th and 75th
percentiles. Therefore, miRNA expression levels were categorised
using quartiles with expression within the first quartile defined as
‘low’, ‘med’ when expression was in the second and third quartiles
and otherwise ‘high’. Multivariate survival analysis was performed
using Cox’s proportional hazard model with ‘med’ and ‘high’
collapsed into one category. The covariates included in the analysis
were evaluated using both forward and reverse stepwise methods.
Correlations with gene expression profiles
Expression profiling was generated using Affymetrix HGU133Plus2
chips (Santa Clara, CA, USA) following manufacturer’s instructions.
Eighty-four samples from patients with TaqMan miR-206 measure-
ments (Table 1) were analysed after normalisation using gcrma
package that included further samples described elsewhere (Wil-
liamson et al, 2010). Probesets were filtered based on their
expression, removing those showing a level o6 (as log2 intensity)
in all samples. Linear regression analysis and Pearson’s product
moment correlation coefficients were calculated dividing patient
samples on the basis of their fusion gene status. Probesets that
showed a correlation with miR-206 expression levels 40.55 and
o–0.5 with a P-value o0.001 were selected for data mining
analysis. Gene ontology was performed using GOstats package using
the hypergeometric test to identify association of biological process
terms. All analysis was performed using R-2.9 software. Ingenuity
Pathway Analysis Software (Ingenuity, Redwood City, CA, USA) was
also used to identify relevant networks and pathways over-
represented in our gene list. A score was computed for each
network that reflects the negative logarithm of the P-value and
indicates the likelihood of genes in a network being found together.
miRNA transfections and cell proliferation assay
Cells were plated at 4 10
3–6 10
3 cells per well in 96-well plates
in sextuplicates and, after 24h, transfected using HiPerfect reagent
with 25nM of synthetic miR-206 (Qiagen GmbH, Hilden, Germany
or Ambion Inc., Austin, TX, USA) or a negative control (AllStars
Negative (Qiagen GmbH) or pre-miR negative (Ambion Inc.).
Transfection efficiency was tested using a FITC labelled oligo. Cell
proliferation of RD and RH30 cells were assessed over a 4-day
time-course and measured using the CyQuant NF kit (Invitrogen,
Carlsbad, CA, USA) according to manufacturer’s instructions.
RUCH3 and RH41 cell viability was assessed at 96h after
transfection using the CellTitre 96 Aqeuous One solution (Promega,
Madison, WI, USA) according to the manufacturer’s instructions.
All measurements from the sextuplicates were averaged.
Cell cycle and apoptosis analyses
In all, 1 10
5cells were plated in a six-well plate and transfected as
described above. Cells were harvested at 72h after transfection,
stained with propidium iodide and analysed by FACS using
a standard protocol (http://www.flemingtonlab.com/Protocols/
PreparingCellsforFACS-PI.pdf). Cell cycle distribution was evaluated
using FlowJo software and Dean/Jett/Fox algorithm (Tree Star Inc.,
Ashland, OR, USA). Apoptosis was evaluated in cells grown in 96-
well plates by measuring caspase-3 and -7 activation 72h after
transfection using Caspase-Glo 3/7 Assay (Promega) according to
the manufacturer’s protocol. All experiments were performed in
triplicate.
In vitro migration assays
Cells were plated in six-well plates and transfected as described
above. At 72 or 96h after transfection, 2.5 10
4 cells in DMEM 1%
FCS were placed in triplicate into cell culture inserts (BD, Franklin
Lakes, NJ, USA) and submerged into specially adapted 24-well
plates (BD) containing 500ml DMEM 10% FCS. Non-migrated cells
were removed 24h later and the base of the inserts fixed in 100%
methanol and stained with 2% crystal violet solution. Cells were
photographed at  10 magnification (four fields of view) and
counted manually. All experiments were performed in triplicate.
Western blot and antibodies
Cells were washed once with ice-cold PBS and lysed in situ with Cell
Lysis Buffer (Cell Signaling, Danvers, MA, USA) according to the
manufacturer’s instructions. Protein was quantified using the BCA
Protein Assay Kit (Thermo Scientific, Waltham, MA, USA) according
to the manufacturer’s instructions. Protein (8–10mg) was resolved
on 4–12% 1.5mm Bis-Tris gels (Invitrogen) and transferred to
PDVF membranes (Invitrogen). Protein was visualised using the ECL
Plus western blotting detection system (GE Healthcare, Little
Chalfont, Bucks, UK) and a ChemiDoc XRS chemiluminescent
detection system (Bio-Rad Inc., Hercules, CA, USA). Anti-MYOG
(F5D) and -MET (code 18321) antibodies were from the Develop-
mental Studies Hybridoma Bank, maintained by the University of
Iowa (Iowa City, IA, USA), and IBL (Gunma, Japan), respectively.
RESULTS
Muscle-specific miRNAs are underexpressed in RMS
compared with normal skeletal muscle
The expression of muscle-specific miRNAs was quantified in 163
primary RMS samples, 4 RMS cell lines, one myoblast sample,
15 normal skeletal muscle and 4 other normal tissues (lung, colon,
brain and thyroid) by quantitative RT–PCR. All miRNAs showed a
statistically significant lower level of expression in RMS compared
with the skeletal muscle samples (Wilcox test, Po0.001) (Figure 1).
With the exception of miR133a, a higher level of expression was
observed in tumours compared with other normal tissue. In
addition, fusion gene negative ERMS and ARMS showed a similar
wide range of expression for all the miRNAs measured. miR-1 was
significantly higher in the ARMS fusion positive compared with all
other RMS (Figure 1 and Supplementary Table 3).
miR-206 expression correlates with overall survival in RMS
Only the expression of miR-206 was significantly inversely
correlated with overall survival when tested as a continuous value
using a Cox proportional hazard model (N¼159, HR 0.93 (95% Cl
0.87–0.98), P¼0.018). The Kaplan–Meier curves show the
correlation between overall survival and expression of miR-206
when categorised into three groups using expression level whereas
this is not the case for miR-1 or miR-133a/b (Table 2, Figure 2B
and Supplementary Table 4). It is noteworthy that lower miR-206
expression was significantly associated with shorter survival in
ERMS and ARMS fusion gene-negative patients (Figures 2A and C,
Table 2). This was not found in patients with ARMS positive
for PAX3/7-FOXO1 (Figure 2D and Supplementary Table 4).
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expression and disease-free survival (data not shown). However, a
significantly higher number of patients relapsed without leading to
death when miR-206 expression was high or median compared with
patients with low expression (high, 22% (9 out of 40); medium, 18%
(14 out of 79); and low, 10% (4 out of 40); w
2 test Po0.001). In
addition, more patients with low miR-206 expression died of
progressive disease, which was not stabilised clinically and in which
there was no disease-free survival to be measured, compared with
those with median or high expression (low, 12% (5 out of 40); medium,
4% (3 out of 79); and high, 2% (1 out of 40); w
2 test Po0.001).
In multivariate analysis miR-206 expression was retained in the
best model (Table 3) when using all RMS samples, although this
did not reach the conventional threshold for statistical signifi-
cance. Similarly, a multivariate analysis was also performed for
fusion gene-negative patients. However, the presence of only
26 events within this group strongly limited the number of clinico-
pathological parameters evaluated in association with miR-206
expression. Nevertheless, expression within the first quartile
retained its independent predictive value for shorter overall
survival in fusion gene-negative cases when combined with either
the presence of bone–bone-marrow or any other metastasis at
diagnosis (Supplementary Table 5). Furthermore, miR-206 expres-
sion was significantly lower in patients with higher SIOP stage and
metastasis at diagnosis (Supplementary Table 3 and Supplemen-
tary Figures 1A and B). When divided by their fusion gene status,
only fusion-negative patients still showed a significant correlation
with these parameters (Supplementary Figures 1C–F).
Expression of miR-206 in primary tumours correlates with
gene expression associated with multiple pathways,
including myogenic differentiation
Gene expression profiling data were analysed for 84 samples that
were also tested for miR-206 expression. Within the fusion gene-
negative samples 149 and 117 known genes showed a significant
positive or negative correlation with miR-206 expression levels,
respectively. Only 3 and 44 genes passed the inclusion criteria in
the fusion gene-positive group as the range of expression in this
group was narrow (Supplementary Table 6).
Data mining of the lists of genes associated with high miR-206
expression in fusion-negative patients performed using Gene
Ontology and Ingenuity Software clearly showed strong correlates
to genes associated with muscle differentiation (Supplementary
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Figure 1 Box and whiskers plots representing the expression of (A) miR-206, (B) miR-1, (C) miR133a and (D) miR133b in 33 ARMS fusion negative
(ARMS_Neg), 45 ARMS PAX3-FOXO1A (ARMS_P3F), 12 ARMS PAX7-FOXO1A (ARMS_P7F), 66 ERMS, 7 RMS not otherwise specified (RMS_NOS),
4 RMS cell lines, 15 normal skeletal muscles (Sk.muscle), 1 myoblasts sample (Myob) and 4 normal tissues. D_CT values were calculated by subtracting
miRNA CT values from the average CT values of two endogenous controls (RNU6B and RNU48).
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sTable 2 Correlation of miR-1, 133a, 133b and 206 with overall survival
All RMS patients Fusion-negative patients
miRNA No. of patients HR (95% CI) Log-rank test (P) No. of patients HR (95% CI) Log-rank test (P)
miR-206 expression
High miR-206 40 1 0.003 31 1 0.005
Med miR-206 79 2.1 (0.9–4.7) 38 2.0 (0.6–6.5)
Low miR-206 40 3.7 (1.7–8.4)** 26 4.9 (1.6–15.0)**
miR-1 expression
High miR-1 40 1 0.515 16 1 0.229
Med miR-1 79 0.9 (0.5–1.6) 45 0.9 (0.5–1.6)
Low miR-1 40 1.2 (0.6–2.5) 34 1.2 (0.6–2.5)
miR-133a expression
High miR-133a 40 1 0.859 21 1 0.314
Med miR-133a 79 1.2 (0.6–2.2) 40 0.9 (0.3–2.9)
Low miR-133a 40 1.2 (0.6–2.4) 34 1.7 (0.6–4.9)
miR-133b expression
High miR-133b 40 1 0.355 21 1 0.161
Med miR-133b 79 1.2 (0.6–2.3) 44 1.4 (0.4–4.3)
Low miR-133b 40 1.6 (0.8–3.3) 30 2.5 (0.8–7.8)
Abbreviations: CI¼confidence interval; HR¼Hazard Ratio; miRNA¼microRNA; RMS¼ rhabdomyosarcoma. **Po0.01.
0 0 5 8 17 40 Low
1 1 9 18 38 79 Med
1 3 4 12 23 40 High
No. at risk
0 0 5 8 16 40 Low
2 4 12 22 43 79 Med
0 0 1 8 19 40 High
No. at risk
0 0 5 7 11 26 Low
1 1 7 12 21 38 Med
1 3 4 11 20 31 High
No. at risk
1 5 15 39 Med
0 1 3 8 High
No. at risk
P = 0.003
High miR-206
Median miR-206
Low miR-206
High miR-206
Median miR-206
Low miR-206
High miR-206
Median miR-206
Low miR-206
High miR-1
Median miR-1
Low miR-1
P = 0.51
P = 0.005 P = 0.74
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Figure 2 Kaplan–Meier plots for overall survival with (A) miR-206 expression (B) miR-1 expression in all RMS samples and (C) miR-206 within fusion
gene-negative patients and (D) miR-206 within fusion gene-positive patients. Expression levels within the first quartile was considered ‘low’, ‘med’ when
expression was between the second and third quartile and ‘high’ when within the top quartile. P-values were obtained using log-rank test.
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sTable 7 and supplementary Figure 2). Low expression of miR-206
in fusion-negative RMS was associated with genes involved
MAPkinase and NF-KappaB signalling as well as IL-4 that is
involved in the immune response.
Transfection of miR-206 in RMS cell lines shows
anti-tumourigenic effects
To further analyse the role of miR-206, ERMS and ARMS cell lines
were transfected with a miR-206 mimic or a negative control.
Transfection efficacy was always above 80%, and miR-206 levels
were comparable to those observed in skeletal muscle (data not
shown). Cell growth and viability were significantly reduced in all
cell lines with a cell cycle delay in G1/G0 phase (Figures 3A and B).
Apoptosis was detected through activation of caspase3/7
(Figure 3C) and confirmed as an increase in the sub G1/G0 cell
population. Cell lines also showed reduction in their ability to
migrate after transfection of miR-206 (Figure 3D). Elevated
miR-206 was linked with a more elongated and differentiated cell
phenotype associated with increased levels of myogenin mRNA
and protein in cell lines RD, RH30 and RH41 but not RUCH3
(Supplementary Figures 3A and B and data not shown). Expression
of the tyrosine kinase receptor MET is associated with migratory
behaviour and has been shown to be a target of miR-206
(Christensen et al, 2005; Yan et al, 2009). Decreased expression
of MET protein was observed at 72 and 96h after transfection
(Supplementary Figure 3C).
DISCUSSION
In this study, we investigated the clinical relevance of expression
levels of the muscle-specific miRNAs miR-1, miR-206, miR-133a
and miR-133b in a large population of primary RMS samples. This
revealed an inverse correlation between miR-206 levels and
adverse outcome in fusion gene-negative cases that is consistent
with underlying molecular mechanisms associated with miR-206
expression levels.
The expression of muscle-specific miRNAs was markedly
reduced in RMS compared with normal terminally differentiated
skeletal muscle. A broad range of expression levels was observed
but these were generally higher than in other normal tissues tested.
In light of evidence for their role in promoting skeletal muscle
differentiation (Kim et al, 2006), it is likely that the low but
detectable levels of miR-1 and miR-206 expression contribute to
the arrested myogenic phenotype of this tumour. Previous analyses
of small series of RMS have also shown low levels of miR-1 and
miR-206 relative to skeletal muscle (Subramanian et al, 2008;
Wang et al, 2008; Taulli et al, 2009; Yan et al, 2009) but
undetectable levels by quantitative RT–PCR are described (Taulli
et al, 2009), which was not the case in our study. miR-1 was
significantly more highly expressed in the fusion gene-positive
ARMS compared with the ERMS or fusion gene-negative ARMS.
This is consistent with the biological and clinical similarities of
ERMS and fusion gene-negative ARMS (Davicioni et al, 2006, 2009;
Williamson et al, 2010). Higher miR-1 levels in fusion gene-
positive cases is also consistent with the fact that ARMS usually
show higher expression of muscle-specific markers such as
myogenin than ERMS (Morotti et al, 2006).
Survival analyses revealed significant correlations between
miR-206 expression levels and overall survival within fusion gene-
negative patients. The lack of correlation with disease-free survival
was attributable to low expression of miR-206 not increasing the
probability of relapse, but an association with more aggressive
tumours. In fact, we also show that low miR-206 expression
significantly correlated with high SIOP stage and the presence of
metastases at diagnosis. It is noteworthy that in the fusion gene-
negative cases, miR-206 expression was an independent predictor
for shorter overall survival when associated with presence of
metastasis or bone/marrow metastasis at diagnosis. miR-206 levels
in fusion gene-negative RMS may have clinical implications
because ERMS currently lack molecular markers indicative of
poor outcome and such patients could benefit from treatment
intensification.
Several lines of evidence suggest that these clinical correlations
are linked to the differentiation status of RMS and the propensity
of undifferentiated cells to migrate and potentially metastasise.
Comparing the gene expression profiling data for primary tumours
with their parallel miR-206 expression levels revealed that miR-206
expression strongly correlated with expression of markers of
muscle differentiation, including myogenin. This is consistent with
a shift in the gene expression profile of RD18 towards
differentiated muscle after miR-206 induction recently observed
by (Taulli et al, 2009). Similarly, we also observed induced
expression of myogenin after transfection of miR-206 mimics in
three of four cell lines. Interestingly, low levels of miR-206
correlated with genes associated with networks centred on
NF-KappaB, ERK and JNK signalling pathways, which are considered
to have a role in RMS development (Wang et al, 2007, 2008; Durbin
et al, 2009; Marampon et al, 2009). Overexpression of genes
associated with immune response and inflammation were also
highlighted. IL-4 signalling was one of the top canonical pathways
identified and activation of the IL-4 pathway has recently been
shown to inhibit myogenin expression and increase the migratory
ability of RMS cells (Nanni et al, 2009).
All four cell lines modulated to overexpress miR-206 showed a
reduction of proliferation and migration, associated with reduced
MET expression, a known target of miR-206 (Taulli et al, 2009; Yan
et al, 2009). However, one cell line did not show any associated
signs of muscle differentiation. miR-206 has been shown to act as a
tumour suppressor in the Hela cell line without a link to induction
of muscle differentiation (Song et al, 2009). miR-206 has also been
associated with metastatic and oestrogen-positive breast cancers
(Adams et al, 2007; Kondo et al, 2008; Tavazoie et al, 2008).
Therefore, miR-206 likely exerts roles distinct from inducing
skeletal muscle differentiation in RMS potentially in a cell
Table 3 Multivariate analysis using Cox proportional hazard model in all
RMS sample
Parameter
a No. of samples
b HR (CI 95%) OS OS P-value
Primary tumour location 0.002
Favourable 50 1
Unfavourable 69 3.1 (1.45–7.33)
Bone or bone marrow metastasis 0.002
No 101 1
Yes 18 3.3 (1.65–6.78)
Fusion gene 0.009
None 74 1
PAX7-FOXO1 10 1.2 (0.37–3.71)
PAX3-FOXO1 35 3.0 (1.43–6.17)
miR-206 expression 0.078
High 96 1
Low 23 1.9 (0.96–3.87)
Abbreviations: ARMS¼alveolar RMS; CI¼confidence interval; ERMS¼embryonal
RMS; OS¼overall survival; RMS¼ rhabdomyosarcoma.
aParameters used in the
stepwise Cox proportional hazard model: primary tumour location (favourable,
unfavourable), presence of metastasis at diagnosis, presence of bone or bone marrow
metastasis at diagnosis, age (favourable o10 years, unfavourable), fusion gene (none,
PAX7-FOXO1, PAX3-FOXO1), histology (ERMS, ARMS), miR-206 expression (low,
high). In particular, miR-206 expression was defined low if within the first quartile and
high otherwise.
bThe stepwise analysis was performed on 116 patients who had
information for all the parameters considered in our model as well as the follow-up,
whereas the final coefficient values were calculated using the number of patients
reported in each column.
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miR-206, and not the other muscle-related miRNAs tested, showed
a statistical correlation with survival data. Analysis of genes
inversely correlated with low miR-1 expression (data not shown)
showed, unlike those for miR-206, strong associations with a
signature for high proliferation. Similarly, miR133a/b has been
specifically associated with myoblast proliferation (Chen et al,
2006). Proliferation rate per se may not relate to adverse patient
outcome with current therapies.
PAX3/7-FOXO1-positive tumours showed no correlations
between miR-206 levels and outcome data. They had a smaller range
of expression levels for miR-206 than fusion gene-negative RMS
and therefore appeared a more homogenous miR-206-expressing
group. PAX3-FOXO1 is a potent transcription factor that affects on
the tumourigenic and myogenic phenotype of RMS (Mercado and
Barr, 2007; Kikuchi et al, 2008). In spite of the lack of clinical
correlations with miR-206 expression levels within this fusion
gene-positive group, introduction of miR-206 into cell lines
expressing PAX3-FOXO1 has been shown here and elsewhere
(Taulli et al, 2009) to have therapeutic potential. Together with our
results showing the expression and clinical correlations of miR-206
in primary RMS, this may lead to novel therapeutic strategies.
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